Macedonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

keratitis/fatigue

Врската е зачувана во таблата со исечоци
НаписиКлинички испитувањаПатенти
12 резултати

[Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis].

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Although many factors that trigger the herpes simplex virus (HSV) reactivation from latency have been reported, how HSV resides in a latent state in the normal human cornea still needs to be defined. We therefore conducted a series of studies regarding various aspects of HSV infections. To

Management of patient with Cogan's syndrome: a case report.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND Cogan syndrome-CS, is a rare autoimmune disease defined as an inflammation of the eyes followed by bilateral audiovestibular symptoms. METHODS This is case report of S. A. male, born on April 18th 1986 from Elbasan, presented with the gastrointestinal, audiovestibulary and eyes disorders,

The ocular effects of intracarotid bromodeoxyuridine and radiation therapy in the treatment of malignant glioma.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Since July 1985, 23 patients have been entered into a phase I/II clinical trial using intraarterial 5-bromodeoxyuridine (BUdR) (400-600 mg/m2 daily for 8.5 weeks) and focal external beam radiotherapy (59.4 Gy at 1.8 Gy daily in 6.5 weeks) in the treatment of malignant gliomas (Kernohan grades 3 and

In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE To evaluate the in vitro efficacy of an ophthalmic drug combination against common corneal pathogens of horses. METHODS Representative isolates of 3 bacterial and 2 fungal corneal pathogens of horses. METHODS Pathogens were subjected to minimum inhibitory concentration (MIC) testing of a
New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A

The long-term course of Lyme arthritis in children.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
METHODS The natural history of Lyme disease is not completely known. We studied the long-term course of Lyme arthritis in 46 children in whom the onset of the disease occurred between 1976 and 1979 and who received no antibiotic therapy for at least the first four years of the illness. RESULTS Of

A tiny tick can cause a big health problem.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Ticks are tiny crawling bugs in the spider family that feed by sucking blood from animals. They are second only to mosquitoes as vectors of human disease, both infectious and toxic. Infected ticks spread over a hundred diseases, some of which are fatal if undetected. They spread the spirochete

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE We conducted a phase I dose-escalation study to define the maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics of alvespimycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, given in combination with trastuzumab. METHODS Patients were treated with trastuzumab

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Background The antibody-drug conjugate PF-06263507 targets the cell-surface, tumor-associated antigen 5T4 and consists of a humanized IgG1 conjugated to the microtubule-disrupting agent monomethylauristatin-F by a non-cleavable maleimidocaproyl linker. In this first-in-human, dose-finding trial

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose-escalation study, the authors investigated IMGN853 in patients with FRα-positive solid tumors. METHODS Patients received IMGN853 on day 1 of a 21-day

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody-drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In this first-in-human study, we assessed the safety
Придружете се на нашата
страница на Facebook

Најкомплетната база на податоци за лековити билки поддржана од науката

  • Работи на 55 јазици
  • Лекови од билки поддржани од науката
  • Препознавање на билки по слика
  • Интерактивна GPS мапа - означете ги билките на локацијата (наскоро)
  • Прочитајте научни публикации поврзани со вашето пребарување
  • Пребарувајте лековити билки според нивните ефекти
  • Организирајте ги вашите интереси и останете во тек со истражувањето на новостите, клиничките испитувања и патентите

Напишете симптом или болест и прочитајте за билки што можат да помогнат, напишете билка и видете болести и симптоми против кои се користи.
* Сите информации се базираат на објавени научни истражувања

Google Play badgeApp Store badge